CoChat
Sign Up
Cited by 1,303Global Health and EpidemiologyMental Health Treatment and AccessGlobal Public Health Policies and Epidemiology

The global burden of neurological disorders: translating evidence into policy

Open access
Feigin, Valery L, Vos, Theo, Nichols, Emma, Owolabi, Mayowa O, Carroll, William M, Dichgans, Martin, Deuschl, Günther, Parmar, Priya +2 more·2020·The Lancet Neurology
DOI 10.1016/s1474-4422(19)30411-9PMC PMC9945815
Open this paper in CoChat — free account

Abstract

Neurological disorders are the leading cause of disability and the second leading cause of death worldwide. In the past 30 years, the absolute numbers of deaths and people with disabilities owing to neurological diseases have risen substantially, particularly in low-income and middle-income countries, and further increases are expected globally as a result of population growth and ageing. This rise in absolute numbers of people affected suggests that advances in prevention and management of major neurological disorders are not sufficiently effective to counter global demographic changes. Urgent measures to reduce this burden are therefore needed. Because resources for health care and research are already overstretched, priorities need to be set to guide policy makers, governments, and funding organisations to develop and implement action plans for prevention, health care, and research to tackle the growing challenge of neurological disorders.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(19)30411-9

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The overall numbers of people with dementia have increased more recently in lower income countries due to greater percentage increase in longevity.

    “The overall numbers of people with dementia have increased more recently in lower income countries due to greater percentage increase in longevity. (5, 6)”

    From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [5]

    The Introduction and Burden of neurological disorders sections link rising numbers of people affected by neurological disorders, particularly in low- and middle-income countries, to population growth and ageing. They do not establish that dementia cases specifically rose more recently in lower-income countries or that a greater percentage increase in longevity there caused the rise. Page numbers were not available in our copy. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 53

  1. [3]Feigin VL, Vos T. Global burden of neurological disorders: from Global burden of disease estimates to actions. Neuroepidemiology 2019; 52: 1– 2. 30472717
  2. [4]GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990 to 2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 18: 439– 58. 30871944 PMC6494974
  3. [5]Feigin VL, Nguyen G, Cercy K, Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016. N Engl J Med 2018; 379: 2429– 37. 30575491 PMC6247346
  4. [7]Zunt JR, Kassebaum NJ, Blake N, Global, regional, and national burden of meningitis, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018; 17: 1061– 82. 30507391 PMC6234314
  5. [8]Stovner LJ, Nichols E, Steiner TJ, Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018; 17: 954– 76. 30353868 PMC6191530
  6. [9]Logroscino G, Piccininni M, Marin B, Global, regional, and national burden of motor neuron diseases 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018; 17: 1083– 97. 30409709 PMC6234315
  7. [11]James SL, Theadom A, Ellenbogen RG, Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 18: 56– 87. 30497965 PMC6291456
  8. [14]Stanaway JD, Afshin A, Gakidou E, Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1923– 94. 30496105 PMC6227755
  9. [15]Feigin VL. Primary stroke prevention needs overhaul. Int J Stroke 2017; 12: 5– 6. 27681891
  10. [16]Feigin VL, Norrving B, George MG, Foltz JL, Roth GA, Mensah GA. Prevention of stroke: a strategic global imperative. Nat Rev Neurol 2016; 12: 501– 12. 27448185 PMC8114177
  11. [17]Allen LN, Pullar J, Wickramasinghe KK, Evaluation of research on interventions aligned to WHO “Best Buys” for NCDs in low-income and lower-middle-income countries: a systematic review from 1990 to 2015. BMJ Glob Health 2018; 3: e000535. PMC5841523 29527342
  12. [19]Hopkins DP, Briss PA, Ricard CJ, Reviews of evidence regarding interventions to reduce tobacco use and exposure to environmental tobacco smoke. Am J Prev Med 2001; 20 (suppl): 16– 66. 11173215
  13. [22]Asaria P, Chisholm D, Mathers C, Ezzati M, Beaglehole R. Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. Lancet 2007; 370: 2044– 53. 18063027
  14. [23]Wilson N. Salt tax could reduce population’s salt intake. BMJ 2004; 329: 918. PMC523164 15485985
  15. [24]Meier PS, Holmes J, Angus C, Ally AK, Meng Y, Brennan A. Estimated effects of different alcohol taxation and price policies on health inequalities: a mathematical modelling study. PLoS Med 2016; 13: e1001963. 26905063 PMC4764336
  16. [25]Delcher C, Maldonado-Molina MM, Wagenaar AC. Effects of alcohol taxes on alcohol-related disease mortality in New York State from 1969 to 2006. Addict Behav 2012; 37: 783– 89. 22436591 PMC3647353
  17. [26]Wagenaar AC, Tobler AL, Komro KA. Effects of alcohol tax and price policies on morbidity and mortality: a systematic review. Am J Public Health 2010; 100: 2270– 78. 20864710 PMC2951962
  18. [27]Chaloupka FJ, Grossman M, Saffer H. The effects of price on alcohol consumption and alcohol-related problems. Alcohol Res Health 2002; 26: 22– 34. 12154648 PMC6683806
  19. [28]Elder RW, Lawrence B, Ferguson A, The effectiveness of tax policy interventions for reducing excessive alcohol consumption and related harms. Am J Prev Med 2010; 38: 217– 29. 20117579 PMC3735171
  20. [30]World Health Organization. Clean air for health: Geneva action agenda: first WHO global conference on air pollution and health—summary report. Nov 1, 2018. https://www.who.int/phe/news/clean-air-for-health/en/ (accessed Feb 22, 2019).
  21. [32]Ouriques Martins SC, Sacks C, Hacke W, Priorities to reduce the burden of stroke in Latin American countries. Lancet Neurol 2019; 18: 674– 83. 31029579
  22. [33]Brainin M, Feigin V, Martins S, Cut stroke in half: polypill for primary prevention in stroke. Int J Stroke 2018; 13: 633– 47. 29461155
  23. [34]World Health Organization. First WHO ministerial conference on global action against dementia, 16–17 March 2015, Geneva, Switzerland: meeting report. Geneva: WHO, 2015. https://apps.who.int/iris/bitstream/handle/10665/179537/9789241509114_eng.pdf (accessed Feb 22, 2019).
  24. [36]Lindsay P, Furie KL, Davis SM, Donnan GA, Norrving B. World Stroke Organization global stroke services guidelines and action plan. Int J Stroke 2014; 9 (suppl A100): 4– 13. 25250836
  25. [37]Rimmer K, Shah H, Thakur K. Expanding medicines for neurologic disorders on the WHO Model List. Neurology 2017; 88: e87– 91. 28265046
  26. [38]Burton A. How do we fix the shortage of neurologists? Lancet Neurol 2018; 17: 502– 03. 29680206
  27. [40]Guo B, Naish S, Hu W, Tong S. The potential impact of climate change and ultraviolet radiation on vaccine-preventable infectious diseases and immunization service delivery system. Expert Rev Vaccines 2015; 14: 561– 577. 25493706
  28. [41]Owolabi M, Miranda JJ, Yaria J, Ovbiagele B. Controlling cardiovascular diseases in low and middle income countries by placing proof in pragmatism. BMJ Glob Health 2016; 1: e000105. PMC5103314 27840737
  29. [43]Fereshtehnejad SM, Vosoughi K, Heydarpour P, Burden of neurodegenerative diseases in the eastern Mediterranean region, 1990–2016: findings from the Global Burden of Disease Study 2016. Eur J Neurol 2019; 26: 1252– 65. 31006162
  30. [44]Kleinman A. Four social theories for global health. Lancet 2010; 375: 1518– 19. 20440871
  31. [45]Andre FE, Booy R, Bock HL, Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ 2008; 86: 140– 46. 18297169 PMC2647387
  32. [46]Towfighi A, Ovbiagele B, Saver JL. Therapeutic milestone: stroke declines from the second to the third leading organ- and disease-specific cause of death in the United States. Stroke 2010; 41: 499– 503. 20075347
  33. [47]Towfighi A, Saver JL. Stroke declines from third to fourth leading cause of death in the United States: historical perspective and challenges ahead. Stroke 2011; 42: 2351– 55. 21778445
  34. [48]Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis 2018; 8: S3– 8. 30584159 PMC6311367
  35. [49]Darweesh SKL, Raphael KG, Brundin P, Parkinson matters. J Parkinsons Dis 2018; 8: 495– 98. 30149463 PMC6218141
  36. [51]Jensen RH, Rasmussen A. Multidisciplinary team approach to headache care. Clin Pract 2012; 9: 181– 88.
  37. [53]Janssen F, Awadallah M, Alhalabi A, Telemedicine in general neurology: use of audiovisual consultation for on call back-up service in an acute care hospital. J Neurol 2018; 265: 880– 84. 29427025
  38. [56]Bond DS, Thomas JG, Raynor HA, B-MOBILE—a smartphone-based intervention to reduce sedentary time in overweight/obese individuals: a within-subjects experimental trial. PLoS One 2014; 9: e100821. 24964010 PMC4071034
  39. [57]Glynn LG, Hayes PS, Casey M, Effectiveness of a smartphone application to promote physical activity in primary care: the SMART MOVE randomised controlled trial. Br J Gen Pract 2014; 64: e384– 91. 24982490 PMC4073723
  40. [58]Krishnamurthi R, Hale L, Barker-Colllo SAT, Mobile technology for primary stroke prevention: a proof-of-concept pilot randomised controlled trial—a brief report. Stroke 2018; 50: 196– 98. 30580699
  41. [59]Feigin VL, Norrving B, Mensah GA. Primary prevention of cardiovascular disease through population-wide motivational strategies: insights from using smartphones in stroke prevention. BMJ Global Health 2017; 2: e000306. PMC5435273 28589034
  42. [60]Wardlaw JM, Bath PM. Stroke research in 2018: extended time windows, refined benefit, and lifestyle prevention targets. Lancet Neurol 2019; 18: 2– 3. 30563678
  43. [61]Linares-Del Rey M, Vela-Desojo L, Cano-de la Cuerda R. Mobile phone applications in Parkinson’s disease: a systematic review. Neurologia 2019; 34: 38– 54. 28549757
  44. [62]Zayas-Garcia S, Cano-de-la-Cuerda R. Mobile applications related to multiple sclerosis: a systematic review. Rev Neurol 2018; 67: 473– 83. 30536361
  45. [63]Stubberud A, Linde M. Digital technology and mobile health in behavioral migraine therapy: a narrative review. Curr Pain Headache Rep 2018; 22: 66. 30066141
  46. [64]Klimova B, Bouckova Z, Toman J. Mobile phone apps as support tools for people with dementia. In: Park J, Loia V, Choo KK, Yi G (eds). Advanced multimedia and ubiquitous engineering: lecture notes in electrical engineering, Singapore. Springer, 2019. 518: 7– 12.
  47. [65]Ryvlin P, Beniczky S. Seizure detection and mobile health devices in epilepsy: update and future developments. Epilepsia 2018; 59 (suppl 1): 7– 8. 29873830
  48. [66]Afra P, Bruggers CS, Sweney M, Mobile software as a medical device (SaMD) for the treatment of epilepsy: Development of digital therapeutics comprising behavioral and music-based interventions for neurological disorders. Front Hum Neurosci 2018; 12: 171. 29780310 PMC5946004
  49. [68]The Lancet Neurology. The data to put neurology on top of the public-health agenda. Lancet Neurol 2019; 18: 1. 30563671
  50. [70]Norrving B, Barrick J, Davalos A, Action plan for stroke in Europe 2018–2030. Eur Stroke J 2018; 3: 309– 36. 31236480 PMC6571507
  51. [71]Gibbs RM, Lipnick S, Bateman JW, Toward precision medicine for neurological and neuropsychiatric disorders. Cell Stem Cell 2018; 23: 21– 24. 29887317
  52. [72]Tan L, Jiang T, Tan L, Yu JT. Toward precision medicine in neurological diseases. Ann Transl Med 2016; 4: 104. 27127757 PMC4828730
  53. [73]Ridler C Artificial intelligence accelerates detection of neurological illness. Nat Rev Neurol 2018; 14: 572. 30166601

Cited by

Sorted by citations

Authors
Feigin, V. L., Vos, T., Nichols, E., Owolabi, M. O., Carroll, W. M., Dichgans, M., Deuschl, G., Parmar, P., Brainin, M., & Murray, C.
Affiliations
  • Auckland University of Technology (NZ)
  • University of Washington (US)
  • University of Ibadan (NG)
  • Sir Charles Gairdner Hospital (AU)
  • Munich Cluster for Systems Neurology (DE)
  • Christian-Albrechts-Universität zu Kiel (DE)
  • Universität für Weiterbildung Krems (AT)
Corresponding author
Feigin, Valery L
ORCID
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2020-03
Volume
19
Issue
3
Pages
255-265
ISSN
1474-4422 (ISSN-L)
DOI
10.1016/s1474-4422(19)30411-9
PMC
PMC9945815
OpenAlex
W2991851654
Cited by
1,303
References
8
Citations by year
2026: 295 · 2025: 337 · 2024: 309 · 2023: 160 · 2022: 116 · 2021: 65 · 2020: 20 · 2019: 1
FWCI
9.50
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
Funders
  • Deutsche Forschungsgemeinschaft
  • Bundesministerium für Bildung und Forschung
  • Bill and Melinda Gates Foundation
  • Boston Scientific Corporation
Topics
  • Health Sciences › Health Professions › Health Information Management › Global Health and Epidemiology
  • Social Sciences › Psychology › Social Psychology › Mental Health Treatment and Access
  • Social Sciences › Business, Management and Accounting › Organizational Behavior and Human Resource Management › Global Public Health Policies and Epidemiology
Keywords
neurological disorders, global burden of disease, disability, mortality, low- and middle-income countries, population aging, health policy, research priorities, prevention, health resources
MeSH terms
Global Burden of Disease, Female, Humans, Life Expectancy, Male, Nervous System Diseases, Quality of Life, Socioeconomic Factors, Global Health, Quality-Adjusted Life Years

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review